A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo

Inclusion Criteria: * Patients ≥ 2 years of age. * Signed written informed consent document by patient, parent, legal guardian or caretaker. * Positive Gram-stain of target lesion showing Gram-positive cocci. * Clinical diagnosis of primary non-bullous impetigo as per protocol. * Candidate for treatment with topical antibacterial and have a Skin Infection Rating Scale (SIRS) of ≥ 4 with at least three of the five primary signs and symptoms present at baseline including a score of 1 or greater for exudate/pus. * Total lesion area ≤ 20 cm2. Single lesion not to exceed 2 cm2. * No known medical conditions that in the investigators opinion may interfere with study participation or put the patient at additional risk. Exclusion Criteria: * Unwillingness or inability of patient, parent, legal guardian or caretaker to comply with the requirements of the protocol. * Presence of other skin disease at or near the investigational target area to be treated. * The disease is so widespread or severe that, in the opinion of the investigator, the patient needs oral antibiotic treatment. * History of hepatitis B or C, HIV, AIDS, or other immunodeficiency disease. * Concurrent or recent scabies infection. * Signs and symptoms of a current infection requiring antibiotic treatment. * Tympanic temperature at Baseline \> 38 °C (100.4 °F) in a pediatric patient or 37.8 °C (100 °F) in an adult patient. * Use of systemic or topical antibiotics or steroids within 72 hours prior to study entry. * Participation in any other clinical study or use of any other investigational drugs or investigational device within 30 days prior to treatment. * Known allergy to any constituent of the study medication. * Presence of secondarily-infected animal/human/insect bite or infected burn wound. * Other reason which based on the discretion of the investigator makes the patient unsuitable for enrolment. * Lactating or pregnant.